Lubiprostone (Amitiza) for chronic constipation

Medical Letter on Drugs and Therapeutics

Volumn 48, Issue 1236, 2006, Pages 47-48

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

LUBIPROSTONE; TEGASEROD; CHLORIDE CHANNEL; DRUG DERIVATIVE; FATTY ACID; GASTROINTESTINAL AGENT; PROSTAGLANDIN E1;

ABDOMINAL PAIN; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; NAUSEA; SHORT SURVEY; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; PREGNANCY;

ALPROSTADIL; CHLORIDE CHANNELS; CHRONIC DISEASE; CLINICAL TRIALS; CONSTIPATION; FATTY ACIDS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; PREGNANCY;

EID: 33745798874     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Tegaserod maleate (Zelnorm) for IBS with constipation. Med Lett Drugs Ther 2002; 44:79.
2. Drugs for irritable bowel syndrome. Treat Guidel Med Lett 2006; 4:11.
3. J Cuppoletti et al. Recombinant and native intestinal cell ClC-2 Cl channels are activated by RU-0211. Gastroenterology 2002; 122 suppl 1:A-538, abstract W955.
4. J Cuppoletti et al. SPI-0211 activates T84 cell chloride transport and recombinant human C1C-2 chloride currents. Am J Physiol Cell Physiol 2004; 287:C1173.
5. M Camilleri et al. Effect of a selective chloride activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290:G942.
6. JP Winpenny. Lubiprostone. IDrugs 2005; 8:416.
7. J Johanson et al. Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation. Gastroenterology 2002; 122 suppl 1:A-315, abstract M15111.
8. J Johanson et al. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology 2003; 124 suppl 1:A-48, abstract 372.
9. J Johanson et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology 2004; 126 suppl 2:A-100, abstract 749.